- Home
- SEZL vs SDGR Comparison
SEZL vs SDGR Comparison
Compare SEZL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- SDGR
- Stock Information
- Founded
- SEZL 2016
- SDGR 1990
- Country
- SEZL United States
- SDGR United States
- Employees
- SEZL N/A
- SDGR N/A
- Industry
- SEZL Diversified Financial Services
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- SEZL Finance
- SDGR Health Care
- Exchange
- SEZL Nasdaq
- SDGR Nasdaq
- Market Cap
- SEZL 1.5B
- SDGR 1.6B
- IPO Year
- SEZL N/A
- SDGR 2020
- Fundamental
- Price
- SEZL $225.00
- SDGR $19.00
- Analyst Decision
- SEZL Strong Buy
- SDGR Buy
- Analyst Count
- SEZL 2
- SDGR 10
- Target Price
- SEZL $366.00
- SDGR $32.90
- AVG Volume (30 Days)
- SEZL 165.4K
- SDGR 624.0K
- Earning Date
- SEZL 02-26-2025
- SDGR 02-26-2025
- Dividend Yield
- SEZL N/A
- SDGR N/A
- EPS Growth
- SEZL 1005.78
- SDGR N/A
- EPS
- SEZL 9.51
- SDGR N/A
- Revenue
- SEZL $221,806,305.00
- SDGR $193,348,000.00
- Revenue This Year
- SEZL $59.52
- SDGR N/A
- Revenue Next Year
- SEZL $33.19
- SDGR $26.50
- P/E Ratio
- SEZL $23.67
- SDGR N/A
- Revenue Growth
- SEZL 49.13
- SDGR N/A
- 52 Week Low
- SEZL $30.41
- SDGR $16.67
- 52 Week High
- SEZL $477.53
- SDGR $33.63
- Technical
- Relative Strength Index (RSI)
- SEZL 38.33
- SDGR 43.08
- Support Level
- SEZL $210.23
- SDGR $18.63
- Resistance Level
- SEZL $324.77
- SDGR $20.20
- Average True Range (ATR)
- SEZL 25.84
- SDGR 1.00
- MACD
- SEZL 0.36
- SDGR -0.15
- Stochastic Oscillator
- SEZL 12.90
- SDGR 19.14
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.